More than half of surgical stapler malfunctions went to hidden FDA database

fiercebiotech | May 31, 2019

The Food and Drug Administration has acknowledged that more than 56,000 never-before-disclosed surgical stapler malfunctions were quietly reported to the agency from 2011 through 2018.
The newly acknowledged reports were detailed in an executive summary for FDA advisers. The agency convened a meeting of experts this week to help it determine whether surgical staplers should be moved out of its lowest-risk category-reserved for simple devices like tongue depressors and bandages-to a higher grade that may require testing and additional oversight. Surgical staplers are used to cut and seal vessels and tissues inside the body.

Spotlight

Watch this user setting up the simple workflow for fully automated microarray scanning. With the combination of GenePix SL50 Microarray
Slide Loader and GenePix Pro Software,
there is complete flexibility to configure automated
scanning and analysis parameters for up
to 50 slides. After scanning, the software can
analyze, run queries and save batch results.

Spotlight

Watch this user setting up the simple workflow for fully automated microarray scanning. With the combination of GenePix SL50 Microarray
Slide Loader and GenePix Pro Software,
there is complete flexibility to configure automated
scanning and analysis parameters for up
to 50 slides. After scanning, the software can
analyze, run queries and save batch results.

Related News

TFF Pharmaceuticals and Felix Biotechnology Sign Letter of Intent for a Collaboration, Development and License Agreement

Felix Biotechnology, Inc. | November 06, 2020

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, and Felix Biotechnology, Inc., a clinical stage, biotherapeutic-based antibiotic development company, today jointly announce that both companies have entered into a letter of intent (LOI) which reflects the parties’ non-binding agreement in principle to negotiate and enter into a Collaboration, Development and License Agreement (CDLA). Under this proposed CDLA agreement, Felix Biotechnology would obtain a worldwide license to TFF Pharmaceuticals’ Thin Film Freezing technology to develop and manufacture dry powder formulations of a novel, bacteriophage-based biotherapeutics for inhalation delivery directly to the lungs of patients. Under the terms of the proposed CDLA and in exchange for the license to the TFF technology, Felix would agree to pay TFF Pharmaceuticals an upfront payment, development milestones, commercial milestones and royalties on net sales of the Felix biotherapeutics. A definitive CDLA is subject to the mutual agreement of the parties and a number of conditions, including Felix Biotechnology’s successful completion of a Series A financing.

Read More

MEDTECH

Aesthetics Biomedical® Announces Collaboration with U.S. Dermatology Partners Offering Consumers Luxury Experiential Aesthetic Treatments

Aesthetics Biomedical® Inc. | October 07, 2021

Aesthetics Biomedical® Inc. (ABM), is pleased to announce their long-term partnership with U.S. Dermatology Partners, the largest physician-led dermatology practice in the United States. With years of experience and more than 90+ locations throughout Arizona, Colorado, Kansas, Maryland, Missouri, Oklahoma, Texas, and Virginia, U.S. Dermatology Partners combines the personal level of care found in private dermatology practices with the benefits of a network of physician experts working closely together. As a result, U.S. Dermatology Partners can provide premier medical and cosmetic dermatological care, along with the latest technology, treatments, and management support. Striving to innovate, generate solid clinical and laboratory research, and to enrich the physician as well as the patient experience are principles that Aesthetics Biomedical® was founded on. It is these foundational principles that have led to our synergy with U.S. Dermatology Partners. -Chief Executive Officer & Founder, MaryAnn Guerra U.S. Dermatology Partners, a pinnacle network of specialty experts found a lifetime partner in excellence and innovation with Aesthetics Biomedical®. Beginning in 2021, U.S. Dermatology Partners installed Vivace® into four initial practices. A pilot project between the two organizations launched the partnership that resulted in over 170 consumer treatments being sold within the first four weeks. U.S. Dermatology Partners and ABM marketed the Vivace Experience® concept with the objective of delivering an immediate ROI supporting the purchase of the initial device for the organization. Vivace® is a primary driver expected to positively impact U.S. Dermatology Partners' market growth exponentially and rapidly, already generating significant revenue in six locations across the US, in under six (6) months. Having access to ongoing knowledge and clinical data is critical to U.S. Dermatology Partners physicians who are committed to continuous and consistent superior patient care. U.S. Dermatology Partners is thrilled to be collaborating with Aesthetics Biomedical® to bring the Vivace Experience® to our patients and our growing network to Aesthetics Biomedical®. We expect the innovative technology and outstanding results that Vivace offers will be well-received by both our physicians and patients and will provide another opportunity to deliver superior care to the communities we serve. - U.S. Dermatology Partners Chief Executive Officer Paul Singh Vivace® is a minimally invasive, FDA-cleared, radiofrequency microneedling treatment that stimulates the natural production of collagen and has been shown by physicians to be effective in alleviating facial wrinkles, fine lines, and tightening the face and neck. Aesthetics Biomedical's Vivace® is currently offered in multiple U.S. Dermatology Partners practices across 50% of the markets nationwide with rapid expansion plans in Q4. ABM will help to drive U.S. Dermatology Partners's practice success with superior technology, devices, and products supported by science, customer-focused market recognition, rigorous and continuing education, and strong continuous return on investment. Both organizations are aligned in their commitment to excellence and share a common goal for elevating the consumer experience at the forefront of the partnership. ABOUT AESTHETICS BIOMEDICAL Aesthetics Biomedical® Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical's innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network, and the aesthetic arena, creating novel patient treatment experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. ABOUT U.S. DERMATOLOGY PARTNERS As one of the largest physician-owned dermatology practices in the country, U.S. Dermatology Partners patients not only have access to general medical, surgical, and cosmetic skin treatment through its coordinated care network, but also benefit from the practice's strong dermatology subspecialty thought leaders and medical advisory board. To be the best partners to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team, therefore, includes recognized national leaders in areas such as clinical research, psoriasis, and Mohs Surgery.

Read More

Sartorius Stedim Biotech Closes Acquisition of Slovenian Purification Specialist BIA Separations

Sartorius | November 03, 2020

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees," said Dr. Joachim Kreuzburg, Chairman of the Board and CEO of Sartorius Stedim Biotech. The total purchase price of the transaction is 360 million euros of which 240 million euros were paid in cash and 120 million euros in SSB shares. Both parties have further agreed on three tranches of earn-out payments based on performance over the next five financial years. SSB has been preparing to integrate BIA Separations so this can now be initiated despite the special conditions prevailing during the pandemic. BIA Separations develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies. BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics, and the company also has a strong presence with such novel drug candidates in the clinical pipeline. Expecting continued very strong double-digit sales growth over the next few years, BIA is forecasted to earn sales revenue of approx. 25 million euros in 2020 at profit margins that will be accretive to the underlying EBITDA margin of the Sartorius Stedim Biotech Group. The transaction is not expected to have any material impact on Sartorius Stedim Biotech's 2020 results.

Read More